We've upgraded our phones and computers... is it time to upgrade our psychiatric medications?

Carmen Kosicek, MSN, PMHNP-BC, is ready to teach nurse practitioners and advanced providers in a fun, innovative way at Real Psychiatry in Scottsdale, AZ.

Want to stay in the loop on the latest novel neuroplastogen for major depressive disorder, DLX-001? Check out this update.

A new report honoring Mohammad Ali and his compassion reminds us of our role in compassionate behaviors.

"In my poem, says another, I can forget I am forgotten. Now I understand being misunderstood..."

A patient discusses their struggles coming to terms with a posttraumatic stress disorder (PTSD) diagnosis after multiple traumatic events, detailing their initial resistance to seeking help, the breakthrough moments in therapy that led to acceptance, and their ongoing journey of healing through various treatment approaches.

Chris Schenewerk, MD, shares how his battle with alcohol addiction transformed his understanding of addiction treatment.

How do Eastern religions, spirituality, and cultural psychiatry shape our understanding of mental health?

Although iclepertin was found to be well tolerated, the agent did not meet endpoints.

Because diagnosis and management of concussions remain challenging, reliable biomarkers can improve effective intervention.

While current antidepressants are associated with improved lives for patients, significant challenges arise. Do we need a new class of antidepressants to address these issues?

How can the field of psychiatry support the peace process in the APA and beyond?

"I begin by remembering my hours as a patient..."

How can personalized care, addressing comorbidities, and focusing on gradual improvement help increase treatment success for alcohol use disorder?

What can we learn from nonverbal cues?

Choosing between these 2 interventions for patients with treatment-resistant depression may rest more on differences in access than in baseline characteristics.

Is there a way to separate the neuroplasticity and therapeutic effects from the hallucinatory and dissociative effects of traditional psychedelics?

“Poets don’t have biographies. The work is their biography.”

A new study suggests some people have genetic predispositions for psychiatric conditions that may influence their risk of divorce.

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how effective screening tools like the Edinburgh Postnatal Depression Scale (EPDS) and PHQ-9, combined with comprehensive clinical assessments, are crucial for accurately identifying postpartum depression during routine prenatal and postnatal visits.

What is the appropriate duration for antipsychotic use and how can you safely taper or discontinue them?

The lates update in lecanemab’s journey: the FDA has accepted the BLA for lecanemab-irmb subcutaneous autoinjector for weekly maintenance dosing.

Are you attending Real Psychiatry this weekend?

DLX-001 is a novel neuroplastogen under development for the treatment of major depressive disorder. Learn more about the latest phase 1 data here.

The FDA grants Breakthrough Device Designation to Spear Bio’s pTau 217 blood test for Alzheimer disease.